Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly what ...

Prurigo nodularis (PN) is a rare skin condition. It causes a rash and lumps to form on your skin, which may be severely itchy. Treatment involves relieving the itching. Share on Pinterest Prurigo ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the ...

Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ® ...

Please provide your email address to receive an email when new articles are posted on . These studies are the first published using Dupixent in this indication. The primary endpoint was met by up to ...

The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...

Prurigo nodularis (PN) is a long-lasting skin condition that causes very itchy, hard bumps, often all over the body. The itch can be so intense that people scratch until the skin breaks, leading to ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic prurigo suffer from anxiety, depression, suicidal ideation, stigmatization, stress and ...

Sanofi and Regeneron’s Dupixent is on fire. A week after scoring the first FDA approval for eosinophilic esophagitis, the drug scored priority review for prurigo nodularis. If it wins the agency's ...